Weight loss jab warning from health watchdog over unborn babies
- The MHRA issued a warning on June 4, 2025, after more than 40 pregnancy reports among women using GLP-1 weight-loss and diabetes drugs in the UK.
- This alert followed concerns the drugs, including Ozempic, Mounjaro, Wegovy, Saxenda, and Victoza, lack safety data for pregnancy and must not be taken while pregnant.
- The MHRA emphasized women must use effective contraception—such as pills, implants, coils, or condoms—and stop the medicine if pregnancy occurs, noting Mounjaro may reduce pill effectiveness.
- The agency reported 26 cases linked to Mounjaro, eight to semaglutide , and nine to liraglutide , urging users to avoid unregulated sellers and consult health professionals.
- This warning suggests patients and healthcare providers must prioritize contraception and drug safety to prevent unintended pregnancies and potential fetal harm from these medications.
42 Articles
42 Articles
How GLP-1 weight-loss drugs can mess with birth control and pregnancy, UK agency warns
Anecdotes abound about “Ozempic babies”—when women wound up with unplanned pregnancies while taking both birth-control and the popular GLP-1 drugs for diabetes or weight loss. But today marks the first official agency warning about the possibility of these drugs—specifically Mounjaro—decreasing the effectiveness of oral contraceptives. “Women taking popular medicines for weight loss and diabetes, sometimes referred to as ‘skinny jabs,’ are bein…
Women Taking Weight-Loss Jabs Warned They Must Use Effective Contraception
Women taking weight-loss jabs are being warned they must use effective contraception. The Medicines and Healthcare products Regulatory Agency (MHRA) issued its first alert to the public regarding contraception and weight loss and diabetes jabs following concerns they may not be used safely. The injections have been previously linked to a “baby boom,” with women reporting online that they have had surprise “Ozempic babies” despite using contracep…
Coverage Details
Bias Distribution
- 52% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage